Abstract
Atrial fibrillation (AF) is an established independent risk factor for stroke. Current guidelines regard AF as binary; either present or absent, with the decision for anti-coagulation driven by clinical variables alone. However, there are increasing data to support a biological gradient of AF burden and stroke risk, both in clinical and non-clinical AF phenotypes. As such, this raises the concept of combining AF burden assessment with a clinical risk score to refine and individualize the assessment of stroke risk in AF - the CHA2DS2VASc-AFBurden score. We review the published data supporting a biological gradient to try and construct a putative schema of risk attributable to AF burden.
| Original language | English |
|---|---|
| Pages (from-to) | 665-673 |
| Number of pages | 9 |
| Journal | EP Europace |
| Volume | 23 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 May 2021 |
| Externally published | Yes |
Keywords
- Atrial fibrillation
- Atrial high rate episodes
- Burden
- Duration
- Stroke
- Systemic embolism